Our Stocks to Watch today include American Exploration Corp. (OTCBB: AEXP), Diverse Media Group Inc. (OTC: DVME), Magnum d'Or Resources Inc. (OTCBB: MDOR), myPhotopipe.com Inc. (OTC: MPPC), eWorld Companies Inc. (OTC: EWRC), Speedus Corp. (Nasdaq: SPDE), IntraOp Medical Corp. (OTCBB: IOPM), Hythiam Inc. (Nasdaq: HYTM), Origin Agritech Ltd. (Nasdaq: SEED), Lifeline Biotechnologies Inc. (OTC: LLBO) and ALR Technologies Inc. (OTCBB: ALRT).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover’s Digest Newsletter and Email Stock Watch Alerts.
AMERICAN EXPLORATION CORPORATION (OTCBB: AEXP)
"Up 42.86% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/AEXP.php
Company Profile: http://www.otcpicks.com/american-exploration-corp.htm
American Exploration Corp. is engaged in the exploration and development of oil and gas prospects with the potential for discovery of new or unconventional hydrocarbon resources in the continental
AEXP News:
September 17 - American Exploration Corp. and Mainland Resources, Inc. Enter Into Letter Agreement to Jointly Develop
American Exploration Corp. (OTCBB: AEXP) (Frankfurt: EQO), a
American Exploration will commit approximately 5000 net acres to the project and Mainland Resources will commit approximately 8500 net acres. This represents a total of 13,500 net acres to the composite project area.
Mainland Resources will act as the Operator of the project area and has agreed to pay 80% of the initial well (drilling and completion costs) for a 51% working interest in the well and total project area. American Exploration will pay 20% of the initial well (drilling and completion costs) to earn a 49% working interest in the well and total project area. The additional costs (ie. drilling, completions etc.) for oil and gas activities on the 13,500 net acre project area will be split on a 49% / 51% basis between American and Mainland respectively.
Mainland has a proven track record in the Haynesville shale having participated in the drilling and completion of two producing wells and a third well that is slated for completion on its lands in DeSoto Parish in
Company President Steve Harding states, "Working with Mainland Resources, Inc. is an ideal situation for American Exploration. They have had great success in the Haynesville shale in
DIVERSE MEDIA GROUP INCORPORATED (OTC: DVME)
"Up 14.29% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/DVME.php
Company Profile: http://otcpicks.com/Newsletter/DVME_eProfile_091709.html
Diverse Media Group, Inc. (OTC: DVME) is an entertainment company that aggregates expertise across all aspects of the media industry. Diverse Media Group has at its core the established 27-year history of its wholly owned subsidiary, Diverse Talent Group. Diverse Talent Group is now the 10th largest
DVME News:
September 16 - Diverse Media Group Inc. (DVME) Finalizes Joint Venture to Create Celebrity Superhero Franchises
Diverse Media Group, Inc. (OTC: DVME) has completed the acquisition of a 50% equity interest in Celebrities in Action, Inc. (“CIA”) in a joint venture to create new superhero character franchises based on real-life Hollywood celebrities. The new characters will be developed with major stars of film, music, television and sports. Plans include original storylines spanning television, film, mobile and home entertainment, video games, publishing, consumer products and merchandising.
Celebrities In Action, Inc. is a vertically integrated entertainment company that develops, produces and distributes proprietary and licensed entertainment content, with a particular focus on animated celebrities.
Diverse Media Group purchased 37,500,000 shares of CIA common stock, representing 50% of all authorized shares of Celebrities In Action, Inc. In exchange, Diverse Media Group agreed to assume CIA's responsibilities in signing up celebrities and/or well-known athletes to participate in the creative joint venture with Stan Lee's POW! Entertainment, Inc. Diverse Media Group also agreed to issue 20,400 shares of its Series A Preferred Stock to Fordee CA Trust, the majority CIA shareholder, exchanged for the acquisition of California PA Trust, a
CIA has an existing joint venture with Stan Lee’s POW! Entertainment banner to develop, produce and distribute animated programming, content and merchandise based on the premise of real-life celebrities in competition against characters from other worlds. Diverse Media Group will identify and secure the celebrity participation and Stan Lee will provide the creative vision to shape these novel superhero personas.
Praised as “a legend” worldwide and honored with his own Hasbro “Marvel Legends” action figure, Stan Lee is associated with such breakthrough superhero characters as Spider-Man®, The Incredible Hulk®, The Fantastic Four®, X-Men®, Iron Man® and Daredevil®. He is also recognized as an innovator in creating new media opportunities and revenue streams for the superhero genre. Among his accomplishments, Stan Lee is credited with leading the expansion of Marvel Comics from a small division of a publishing house to a multimedia corporation, and developing his characters into longstanding franchises.
Lee’s POW! Entertainment company has a first-look deal with Disney, which last month acquired his former company, Marvel Comics, for $4 Billion.
MAGNUM D'OR RESOURCES (OTCBB: MDOR)
Detailed Quote: http://www.otcpicks.com/quotes/MDOR.php
Company Profile: http://www.otcpicks.com/magnum-resources/magnum-resources.htm
Magnum d'Or Resources, Inc. focuses in operating in recycling and waste management sectors. It intends to develop facilities that produce rubber powders, thermoplastics, and thermoplastics elastomers. Magnum holds licensing rights to various patents that would allow rubber to be devulcanized, specialty blend EPDM powders, and EPDM compounds. The company was founded in 1999 and is based in
MDOR News:
September 17 - Emerging Stock Report Initiates Independent Research Coverage on Magnum d'Or Resources Inc.
Emerging Stock Report, a leading provider of sector specific independent investment research, initiated coverage on Magnum d'Or Resources Inc. (OTCBB: MDOR). Emerging Stock Report is currently offering a complimentary trial subscription. To view the company's research, go to www.emergingstockreport.com.
September 16 - Greentech International Advisors Announces Shareholder Update for MDOR and Releases Key Data on New Positive Developments
Greentech International Advisors, Inc announces key data on Magnum D'Or Resources, Inc. (OTCBB: MDOR), a next generation rubber recycling solutions company. Recent news headlines regarding MDOR have claimed major property acquisitions as well advancements entailing revolutionary custom compounds and their uses worldwide; such claims have attracted a significant number of international investors and caused an increase in liquidity and appreciation of share price. Therefore, and due to many recent developments Greentech, would like to announce the following:
First, Greentech has been in contact and negotiations with large financial institutions regarding establishing strong equity positions in MDOR. The results of such contacts will be revealed as well as the identities of such institutions in the very near future and upon completion of all necessary documentation.
Second, Greentech has received many enquiries regarding the current filming of the Magog and
Third, that Magnum SRI is currently in possession of the test results for the Revolutionary Light Truck Custom Compound and will release the results publicly by or before Sept 19th, 2009.
Fourth, Magnum will be updating the market with some new positive developments in the next two weeks, regarding its progress in relation to engineering, equipment and operation of its newly acquired 120+ acre facility and tire landfill in
Greentech is very excited to be involved with Magnum and is looking forward to the exciting weeks ahead. Moreover, Greentech is confident that the weeks to come will unveil more substantial achievements and positive news which will significantly advance Magnum and position it as a world leader in the market of recycled tires, rubber, and compounds.
MYPHOTOPIPE.COM INCORPORATED (OTC: MPPC)
Detailed Quote: http://www.otcpicks.com/quotes/MPPC.php
Company Profile: http://www.otcpicks.com/myphotopipe/myphotopipe-2.htm
MyPhotopipe.com Inc. is a US-based provider of online digital photo processing and related services catering to high-end amateur and professional photographers. The Company’s primary web portal is www.myphotopipe.com. Its services include photo finishing and printing, online sharing, photo books, digital photo templates, and online hosting and selling of photographs. The Company provides services to more than 18,500 professional and high-end amateur photographers nationwide; more than 190,000 copies of its software have been downloaded and are in use.
MPPC News:
September 16 - myPhotopipe.com Launches Technology Platforms for Retail and Commercial Users
myPhotopipe.com, Inc. (OTC: MPPC) announced the completion of a suite of online digital photo tools that will allow retailers and other vendors to seamlessly integrate with the Company's photo print lab and purchase print processing services.
"This is huge for us and for our customers," stated Darren Schiff, Chief Operating Officer of myPhotopipe.com, Inc. "There are hundreds of web sites and retailers that offer prints to their customers. Until now, they had few, if any, options for high quality print fulfillment and were literally forced to work with high-volume, low-end processors. That doesn't work if quality is the name of the game and better quality prints are in high demand. These companies can now access our professional lab for back-end fulfillment, using an entirely automated suite of web-based tools. They get professional prints at competitive prices and are able to seamlessly access the capabilities of a professional lab. We believe we are the first professional lab to offer this level of integration."
Schiff estimated that the Company's new Application Programming Interface ("API") will allow myPhotopipe.com to compete for the tens of millions of dollars that are currently funneled to print processors through independent front-end retailers and photo hosting sites. "Because prints are family treasures that last a lifetime, quality has become a defining feature," noted Schiff. "By writing to our API, we provide these retailers with access to high quality, professional services and the finest prints in the nation. The retailers own the customers. We handle the fulfillment. Everyone wins."
The Company's proprietary API allows myPhotopipe.com to serve as the back-end provider to any web site or retailer that offers prints to its customers. This includes fashion sites that provide composition prints for models, sites used by professional photographers to sell "event" photos, and countless others that earn revenues for the processing of digital photos into prints.
Schiff expects an incremental revenue bump from the onset, with the potential to double corporate revenues though API services. "It's all about servicing the digital age with better features and a professional back-end product," said Schiff. "We expect to announce our first customer for this service within the next few weeks."
EWORLD COMPANIES INCORPORATED (OTC: EWRC)
Detailed Quote: http://www.otcpicks.com/quotes/EWRC.php
Company Profile: http://www.otcpicks.com/eworld-companies/eworld-companies.htm
eWorld Companies, Inc. is an online marketing & advertising technologies company that develops and markets cutting edge technologies using rich media, flash, animation and 3D graphics to help individuals and businesses market and advertise online. eWorld's revenue model consists of seven components: (1) Affiliation Fees, (2) Affiliate Monthly Subscriptions, (3) Affiliate Benefit Subscriptions, (4) Product Sales, (5) Advertising Revenues, (6) Web Development Accounts, and (7) International Licensing Fees.
EWRC News:
September 17 - CEO Henning Morales Goes to
eWorld Companies, Inc. (OTC: EWRC) and the National Hispanic Foundation for the Arts have agreed to a series of cross-promotional efforts to promote one another's activities and charitable causes. The program got under way this week in
eWorld and NHFA will continue to work together on a series of additional activities, including eWorld's sponsorship of a special fund-raising event for NHFA's charitable causes, which will take place in
The NHFA was co-founded by Jimmy Smits, Sonia Braga, Esai Morales, Merel Julia (widow of Raul Julia), and Washington, D.C. attorney Felix Sanchez, to increase participation of Hispanics in the entertainment industry. The Foundation offers graduate scholarships and an outreach program at prominent colleges and universities for young Latinos aspiring to careers in entertainment and media. It also seeks to expand career opportunities for existing talent in all aspects of entertainment, telecommunications and performing arts.
SPEEDUS CORPORATION (NASDAQ: SPDE)
"Up 140.62% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SPDE.php
Speedus Corp., through its subsidiaries, engages in healthcare, restaurant, and wireless businesses in the
SPDE News:
September 17 - Zargis Receives FDA Clearance for Signal X6 Telemedicine Device; OK Allows Delivery to US Army
Zargis Medical Corp., a spin-off from Siemens Corporate Research (NYSE: SI) and a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), announced that it has received U.S. Food and Drug Administration (FDA) clearance to market its new Signal X6™ device. Zargis also announced the delivery of seven Signal X6 devices to the U.S. Army for deployment in six Department of Defense medical facilities.
Signal X6 is noninvasive, easy to use and simultaneously records heart and lung sounds from six adhesive sensors. The recordings can be evaluated locally or, for locations where a cardiac specialist is not immediately available for consultation, transmitted through the Internet for remote evaluation. Signal X6 and our recently launched Zargis Cardioscan™ device were both designed for user-friendly digital heart sound analysis. The configuration of the Signal X6 provides a unique telemedicine resource in situations where evaluations would benefit from high fidelity multi-channel synchronous recordings.
"As healthcare systems continue to demand improved outcomes with utilization of fewer resources, we believe that Signal X6 will provide cost-effective, high quality cardiac analysis in situations where it's not practical for a patient to visit a specialist," said John Kallassy, Zargis' CEO.
Prototypes for Signal X6 were first developed with funding from the Telemedicine and Advanced Technology Research Center (TATRC) through the AAMTI program. The AAMTI program provides funding to AMEDD personnel to demonstrate technology and document the impact on cost, access and quality of care. TATRC (www.tatrc.org) is an element of the United States Army Medical Research and Materiel Command (USAMRMC).
ABOUT ZARGIS MEDICAL CORPORATION
Zargis Medical Corp. develops advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals. Zargis was formed in 2001 when Siemens Corporate Research, a division of Siemens AG (NYSE: SI), and Speedus Corp. co-invested to develop and market an advanced acoustic technology designed to detect heart abnormalities identified through analysis of heart sounds.
INTRAOP MEDICAL CORPORATION (OTCBB: IOPM)
"Up 20.59% in morning trading"
Detailed Quote: www.otcpicks.com/quotes/IOPM.php
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively — for all cancer patients. The company’s flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, immediate palliative effect, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics world-wide are increasingly using the Mobetron to treat a wide variety of cancers as a vital part of their comprehensive cancer program.
IOPM News:
September 15 - Groundbreaking Breast Cancer Radiation Technique Delivers Proven Long-Term Benefits and Saves Lives
One minute of radiation in the operating room (OR) could save the lives of thousands of women being treated for breast cancer in the
Now, a portable, self-contained radiation therapy system, the Mobetron from IntraOp Medical Corporation (OTCBB: IOPM) in
Felix Sedlmayer, MD, one of the world’s leading IOERT researchers and the principal investigator of IOERT boost trials conducted by six European medical centers over the past decade, concluded that IOERT cut breast cancer five year recurrence rates dramatically, from an average of 5% to less than 1%.
“If the IOERT boost were a standard technique in the US, every year, more than 5000 breast cancer recurrences could have be avoided,” according to Roland Reitsamer, MD, a surgeon at the University of Salzburg, where the technique has been studied extensively for the past decade. Each one of those recurrences typically would result in a subsequent mastectomy, which also would be avoided. A prestigious Lancet review of studies on breast cancer found a 25% increase in 15 year survival for patients with no recurrences at five years, suggesting that IOERT boost could have a significant impact on the survival of thousands of women worldwide.
What Every Woman Should Know About Intraoperative Radiation
It seems a matter of common sense. Lumpectomy is typically followed by a six-week course of radiation therapy to help eliminate any remaining malignant cells. Treatment takes place at least four weeks after surgery when the breast has healed. Because traditional, post-operative radiation is delivered externally, it must pass through the body to reach diseased areas, and healthy tissue may be damaged in the process. Additionally, once surgery is complete, physicians no longer have direct access to the target area to easily and precisely deliver radiation.
So why not begin the radiation treatment during the surgery itself? This would immediately target any remaining cancer cells, while allowing complete access to the tumor area for greater precision in radiation delivery. It also would spare radiation dose to surrounding tissue and reduce the number of days a woman has to travel to a cancer center for external treatment after surgery. In fact, at
“The answer is that intraoperative radiation simply hasn’t been practical until now,” explains John Powers, CEO for IntraOp. ”Without the Mobetron, the treatment would mean equipping a special operating room with a costly, unwieldy 18,000 pound linear accelerator to generate radiation as well as a shielded radiation vault to protect staff from repeated exposure to this radiation. This is just not feasible for most hospitals.”
The other alternative, Mr. Powers points out, has been transferring patients under anesthesia with an open incision from the OR to a radiation therapy center, typically located offsite. This significantly increases the risk and duration of surgery and anesthesia. The result: despite its enormous benefits, IOERT has rarely been used in the
However, IOERT has been heavily investigated in major European university hospitals and is currently in use in more than a dozen facilities. This is not surprising because historically the European medical system has been an early adopter of promising new paradigms for breast cancer diagnosis and treatment, including mammography, breast conserving lumpectomy and sentinel node biopsy.
The Mobetron
Specifically optimized for IOERT, the IntraOp Mobetron incorporates a range of technological innovations to make all the benefits of this treatment realistic and practical for women and their doctors around the world. The innovative system eliminates the risk, time, cost and complexity of IOERT by enabling delivery in any standard OR.
Unlike conventional linear accelerators, the Mobetron is relatively lightweight and can be wheeled among different OR locations. The Mobetron requires no external radiation vault or bunker because patented technologies eliminate most stray room radiation generated by conventional accelerators and because of its patented self-shielding,
To operate the device, following tumor excision, a Mobetron applicator tube is temporarily inserted into the breast to provide precise treatment directly to the tumor bed. The Mobetron is positioned for radiation delivery, and the one-minute treatment takes place.
HYTHIAM INCORPORATED (NASDAQ: HYTM)
"Up 18.71% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/HYTM.php
Hythiam, Inc. provides through its Catasys subsidiary, specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Catasys substance dependence program was designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term care coaching, including the proprietary PROMETA® Treatment Program for alcoholism and stimulant dependence. The PROMETA Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers. Hythiam does not practice medicine or manufacture, distribute, or sell any medications and has no relationship with any manufacturers or distributors of medications used in the PROMETA Treatment Program.
HYTM News:
September 17 - Hythiam Enters into Agreement with Ford Motor Company for Catasys Integrated Substance Dependence Solution
Hythiam, Inc. (Nasdaq: HYTM) announced that the Company has entered into a three year agreement with Ford® Motor Company to provide the Catasys® integrated substance dependence solution to Ford’s hourly employees in Michigan enrolled in the National PPO and who meet certain criteria. Eligible employees struggling with alcoholism, stimulant and opiate dependence will be covered under the program, which contains medical interventions including naltrexone, Suboxone® and the proprietary PROMETA® Treatment Program, and psychosocial and care coaching components across 52 weeks. The Company will conduct direct outreach to enroll qualified members, and will also work with UAW-Ford and Ford’s EAP program to ensure the most beneficial treatment pathway for members. Contractual revenues from the agreement are based on a combination of monthly fees for the member population for Catasys, with additional monthly fees for members enrolled into the Catasys program. Operational implementation is expected to begin shortly, and the program is anticipated to launch in the fourth quarter of 2009.
“We are pleased by the level of support we received from UAW-Ford and Ford’s management personnel,” said Terren Peizer, Hythiam’s Chairman and CEO. “Our ability to engage and contract with employers and health plans highlights the flexibility of our program to address substance dependence challenges faced by diverse payors and their member populations. We have realigned our company and developed Catasys for the managed care market, and it is rewarding to have a new agreement that further publicly validates our product and business model. Ford’s desire to improve employee care and productivity demonstrates a significant opportunity for health plans to provide their customers the Catasys solution. We look forward to additional agreements over the coming months, and we remain focused on providing effective solutions that enhance member care and improve clinical outcomes, resulting in lower total health care costs. This is especially important as payors face multiple challenges including the recently passed mental health parity and addiction equity bill (Wellstone Domenici Mental Health Parity and Addiction Equity Act of 2008), and increasing budgetary constraints at a time of rising substance dependence rates due to the current economic environment.”
Various studies, research and other resources demonstrate that:
* Problems related to alcohol and drug abuse cost American businesses roughly $81 billion in lost productivity each year.
* 77% of illicit drug users in the
* 500 million workdays are lost annually due to alcoholism.
* Up to 40% of industrial fatalities and 47% of industrial injuries can be linked to alcohol use and alcoholism.
* Employees who use drugs are 3.6 times more likely to be involved in a workplace accident and 5 times more likely to file a workers’ compensation claim.
* Employees who use drugs are 2.2 times more likely to request early dismissal or time off, 2.5 times more likely to have absences of eight days or more, and 3 times more likely to be late for work.
Catasys is focused on improving member care and providing better clinical outcomes in an effort to reduce overall health care costs. Catasys was designed to manage substance dependence as a chronic disease, with a focus on integration between evidence-based medical and psychosocial elements in an outpatient setting, combined with care coaches who will guide and assist members with long-term recovery. Catasys includes identification, engagement, treatment, coaching and ongoing monitoring components directed at providing members with a customized pathway to recovery. The delivery of the program’s medical and psychosocial components is conducted by a trained specialty network of providers who are addiction specialists, and who organize care with care coaches through Catasys’s IT technology platform. Catasys also conducts outreach to qualified members and coordinates with client resources to enroll them in the program, including a focus on reducing barriers to treatment.
ABOUT HYTHIAM® AND CATASYS®
Hythiam, Inc. provides through its Catasys subsidiary, specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Catasys substance dependence program was designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term care coaching, including the proprietary PROMETA® Treatment Program for alcoholism and stimulant dependence. The PROMETA Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers. Hythiam does not practice medicine or manufacture, distribute, or sell any medications and has no relationship with any manufacturers or distributors of medications used in the PROMETA Treatment Program.
ORIGIN AGRITECH LIMITED (NASDAQ: SEED)
"Up 29.65% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SEED.php
Founded in 1997 and headquartered in
SEED News:
September 17 - Origin Agritech Limited Reaches Agreement for Novel Glyphosate-Tolerance Gene
Worldwide Rights for Genetically Modified (GM) Corn, Soybean, Rice, Cotton, and Canola products
Origin Biotechnology, a wholly-owned subsidiary of Origin Agritech Limited (Nasdaq: SEED) announced it has reached an comprehensive, worldwide agreement with the Institute of Microbiology of the Chinese Academy of Sciences (CAS) and Sichuan Biotech Engineering, Limited. CAS and Sichuan Biotech jointly own the rights to an internally developed gene which is highly tolerant to glyphosate (herbicide). This glyphosate-tolerance gene, demonstrated to be extremely effective in both laboratory and field environments, is entirely new to the consumer markets in that it has never been commercialized, and is protected by patents granted separately by
For the entire life of the patent, Origin Biotechnology will receive exclusive rights to sell and develop corn, soybean, rice, cotton and canola products that contain these technology traits worldwide, both in the territory within
As a result of this landmark agreement for Origin, Chairman Gengchen Han reiterated, “Origin continues to demonstrate that it is the leading, technology-focused crop seed company in
UPDATE OF ORIGIN GM PROGRAM
Phytase
World’s first transgenic phytase corn is expected to be commercially launched as the first genetically modified corn product in
Glyphosate (Herbicide) Tolerance
Glyphosate tolerance has passed the intermediate testing phase (Phase 2) and entered the environmental release testing phase (Phase 3). Worldwide, the largest segment of the transgenic crop market has been herbicide tolerant crops. Specifically, glyphosate tolerant crops have been widely accepted in cotton, corn, and canola in
Since their introduction in 1996, over 75 million acres of genetically engineered glyphosate-tolerant crops have been planted, making up 46% of the corn, 80% of soybean acres, and 70% of cotton acres in the
Bt crops produce a protein toxic to specific insects used in areas with high levels of infestations of targeted pests. Bt cotton, which controls varieties of the budworm and bollworm, was planted on 59 percent of
LIFELINE BIOTECHNOLOGIES INCORPORATED (OTC: LLBO)
"Up 18.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/LLBO.php
Lifeline Biotechnologies, Inc. operates as a medical technology company in the
LLBO News:
August 31 - Lifeline Biotechnologies Files Additional Patents on Its First Warning System
Lifeline Biotechnologies, Inc. (OTC: LLBO) announced that it has filed four additional patents on its First Warning System™ methods and technology.
The First Warning System™ has been designed, developed and tested, a process that assists in identifying abnormalities of the breast.
Jim Holmes, Lifeline’s CEO, said that “We are extending patent protection on our proprietary neural net diagnostic technologies with the filing of three additional patent applications in the
Lifeline Biotechnologies previously received two patents on its First Warning System™ hardware and has in the past year filed for a patent on the technological advancements of the First Warning System ™ software. The software has achieved the robust capability of identifying and classifying tissue abnormalities of the breast with sensitivities (ability to identify) of 95% to 100% and specificities (verify) of 87% to 90%. Currently, it is widely recognized that mammograms miss an estimated 20 to 30% of the breast cancers.
Lifeline competes in the money markets for funds to continue the development of its products as well as supporting operating and administrative expenses. The cost of funds for companies such as Lifeline is expensive and the terms have been, and may continue to be, dilutive. The Company is seeking other means of financing in an effort to reduce the dilutive aspects.
ALR TECHNOLOGIES INCORPORATED (OTCBB: ALRT)
"Up 22.22% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ALRT.php
The ALRT Health-E-Connect Disease Management System is designed to enhance compliance of prescribed therapies and report diagnostic data from a number of devices to health professionals for monitoring of patients. The System facilitates cost effective continued oversight of patients by authorized health professionals in-between visits to their physician.
ALRT News:
September 14 - Patent Application Approval for Remote Monitoring of Patient's Use of Nebulizer Compressors Facilitates Enhanced Coordination of Care for Patients With Respiratory Disease
ALR Technologies (OTCBB: ALRT) announces that it has received notice from the US Patent and Trademark Office that ALRT has been granted approval of its patent application regarding patient compliance and remote monitoring of patient's use of nebulizer compressors. This approval from the
COPD is one of the leading causes of death in the world. With 16 million people in the
The use of monitoring-ready nebulizer compressors and ALRT's Health-E-Connect health management communications system can become an important new service provided by health professionals. Furthermore, the Health-E-Connect system is on target with the growing recognition in the
ALRT announced earlier this year that insurance carriers will reimburse physicians for the remote care of patients with the use of its Health-E-Connect system. This will result in new revenue for physicians as they provide the additional service to their patients with respiratory disease. ALRT's Health-E-Connect and complementary Constant Health Companion is the only system in the
OTCPicks.com is located at
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org.
Disclosure: OTCPicks has been compensated two thousand five hundred dollars from a non-controlling third party (BlueWave Advisors) for AEXP advertising and promotional services. OTCPicks has been compensated ten million free trading shares from a non-controlling third party (Microcap Management) for DVME advertising and promotional services. OTCPicks has been compensated ten thousand dollars from a non-controlling third party (GREEN TECH INTERNATIONAL ADVISORS) for MDOR advertising and promotional services. OTCPicks.com has been compensated four hundred thousand free trading shares from a non-controlling third party for MPPC advertising and promotional services. OTCPicks.com is being compensated eight thousand dollars by a third party for MPPC advertising and promotional services. OTCPicks.com is being compensated eight thousand dollars by a third party (Mickey Reno) for EWRC advertising and promotional services. OTCPicks.com has been compensated six thousand dollars by a third party (Mercom Capital) for ALRT advertising and promotional services. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. OTCPicks.com is a website partially owned by BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.
